moneyheap
CYTK · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Cytokinetics Inc. (CYTK) stock moving?
Cytokinetics reported Q3 2026 results on Nov 4 that beat consensus: sales were $47.6M against $41.9M expected, and the loss per share was $(1.37) against $(1.44). MYQORZO net product revenue reached $44.5M, and the company holds about $1.6B in cash and investments. The stock nonetheless fell 12.7% on Nov 5, from $63.60 to $55.55, on 6.78M shares, about three times the prior sessions' volume. The news items do not state the cause of that drop. Analysts stayed constructive: Citigroup kept a Buy and raised its target to $105, Leerink kept Outperform but cut its target to $100, and RBC expects MYQORZO to add to revenue from 2027. Shares fell to a $53.69 low on Nov 6, then recovered to $56.18 on Nov 10 as volume eased to 2.36M. The stock still trades about 12% below its Nov 4 close. Upcoming catalysts include an FDA decision on a MYQORZO label update, a planned supplemental NDA for non-obstructive HCM in Q4 2026, and the EU Type II variation in early 2027. Those events are still ahead and their outcomes are not yet known.
News behind the analysis
- Cytokinetics Reports Third Quarter 2026 Financial ResultsCytokinetics reported Q3 2026 net product revenue of $44.5M for MYQORZO and about $1.6B in cash and investments. The company expects to submit a supplemental NDA for non-obstructive HCM in Q4 2026.
- Cytokinetics Q3 EPS $(1.37) Beats $(1.44) Estimate, Sales $47.557M Beat $41.879M EstimateQ3 loss per share was smaller than expected and sales came in about 14% above consensus.
- Leerink Partners Maintains Outperform on Cytokinetics, Lowers Price Target to $100Leerink kept its Outperform rating and cut its price target from $103 to $100.
- Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105Citigroup kept its Buy rating and raised its price target to $105 after the quarter.
- RBC Capital Markets Comments on Cytokinetics' Myqorzo Revenue PotentialRBC said Myqorzo could start to positively affect Cytokinetics' revenue from 2027.
- Cytokinetics Presents New Aficamten Data at HCMS Scientific SessionsCytokinetics presented new aficamten data from ACACIA-HCM and FOREST-HCM at the HCMS Scientific Sessions.
- Cytokinetics Seeks FDA Label Update for MyqorzoCytokinetics is awaiting an FDA decision on a label update for Myqorzo that would add Phase 3 MAPLE-HCM results.
- Cytokinetics Announces Three Aficamten Presentations, Including Two Late-Breaking Orals In Non-Obstructive Hypertrophic Cardiomyopathy, On November 6Cytokinetics announced three aficamten abstracts, including two late-breaking oral presentations, for the HCMS Scientific Sessions.
- Cytokinetics Announces Participation in Upcoming November Investor ConferencesManagement will attend three investor conferences in November 2026.
About Cytokinetics Inc.
Cytokinetics is a South San Francisco biopharmaceutical company that makes drugs targeting muscle function, especially in the heart. It began selling its first product in 2026: MYQORZO (aficamten), a cardiac myosin inhibitor approved in the US, Europe and China for obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle thickens.
How it makes money
Most of its revenue now comes from MYQORZO sales, which started in the US in early 2026 and in Germany in the second quarter (about $25 million in net product revenue in Q2 2026). It also earns license, milestone and royalty income from partners: Sanofi sells the drug in China and Bayer works with it on Japan. The company still loses a lot of money (a net loss of about $595 million in the first nine months of 2026) and relies on roughly $1.6 billion in cash and investments to fund its launch and research.
What usually moves CYTK
- MYQORZO prescription growth and launch updates
- FDA decision on expanding use to non-obstructive HCM
- Clinical trial results for aficamten and other pipeline drugs
- Competition from Bristol Myers Squibb's Camzyos
- Cash burn and possible need for new funding